MX2022014903A - Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. - Google Patents
Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.Info
- Publication number
- MX2022014903A MX2022014903A MX2022014903A MX2022014903A MX2022014903A MX 2022014903 A MX2022014903 A MX 2022014903A MX 2022014903 A MX2022014903 A MX 2022014903A MX 2022014903 A MX2022014903 A MX 2022014903A MX 2022014903 A MX2022014903 A MX 2022014903A
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- small cell
- cell lung
- treatment
- egfr tki
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030372P | 2020-05-27 | 2020-05-27 | |
| PCT/EP2021/063992 WO2021239786A1 (en) | 2020-05-27 | 2021-05-26 | Egfr tkis for use in the treatment of non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014903A true MX2022014903A (es) | 2023-01-04 |
Family
ID=76181131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014903A MX2022014903A (es) | 2020-05-27 | 2021-05-26 | Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20210369709A1 (enExample) |
| EP (1) | EP4157267B1 (enExample) |
| JP (1) | JP2023529812A (enExample) |
| KR (1) | KR20230017830A (enExample) |
| CN (2) | CN115776889A (enExample) |
| AU (1) | AU2021279171A1 (enExample) |
| BR (1) | BR112022023519A2 (enExample) |
| CA (1) | CA3183434A1 (enExample) |
| DK (1) | DK4157267T3 (enExample) |
| FI (1) | FI4157267T3 (enExample) |
| IL (1) | IL298216A (enExample) |
| MX (1) | MX2022014903A (enExample) |
| TW (1) | TW202216149A (enExample) |
| WO (1) | WO2021239786A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022526159A (ja) | 2019-03-29 | 2022-05-23 | アストラゼネカ・アクチエボラーグ | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
| US12649792B2 (en) | 2019-05-06 | 2026-06-09 | Brown University | Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells |
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
| WO2024118611A2 (en) * | 2022-11-28 | 2024-06-06 | Brown University | Treatment of epidermal growth factor receptor mutant non-small cell lung cancer |
| CN117298116A (zh) * | 2023-08-08 | 2023-12-29 | 江苏晨泰医药科技有限公司 | 盐酸佐利替尼制剂 |
| CN121177212B (zh) * | 2025-11-25 | 2026-03-03 | 中南大学湘雅二医院 | 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| DK3686193T3 (da) * | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| LT2964638T (lt) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai |
| ES3069593T3 (en) | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN105315259B (zh) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| EP3205650B1 (en) | 2014-10-11 | 2021-08-04 | Shanghai Hansoh Biomedical Co., Ltd. | Egfr inhibitor, and preparation and application thereof |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| AU2015360360B2 (en) | 2014-12-11 | 2020-06-25 | Beta Pharma (Shanghai) Co., Ltd. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
| CN107614503B (zh) | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
| EP3661519A1 (en) * | 2017-08-03 | 2020-06-10 | Novartis AG | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
-
2021
- 2021-05-25 US US17/329,229 patent/US20210369709A1/en not_active Abandoned
- 2021-05-26 IL IL298216A patent/IL298216A/en unknown
- 2021-05-26 CA CA3183434A patent/CA3183434A1/en active Pending
- 2021-05-26 CN CN202180037402.7A patent/CN115776889A/zh active Pending
- 2021-05-26 AU AU2021279171A patent/AU2021279171A1/en active Pending
- 2021-05-26 FI FIEP21728553.5T patent/FI4157267T3/fi active
- 2021-05-26 WO PCT/EP2021/063992 patent/WO2021239786A1/en not_active Ceased
- 2021-05-26 JP JP2022572309A patent/JP2023529812A/ja active Pending
- 2021-05-26 EP EP21728553.5A patent/EP4157267B1/en active Active
- 2021-05-26 KR KR1020227045541A patent/KR20230017830A/ko active Pending
- 2021-05-26 BR BR112022023519A patent/BR112022023519A2/pt unknown
- 2021-05-26 CN CN202610610034.5A patent/CN122376595A/zh active Pending
- 2021-05-26 MX MX2022014903A patent/MX2022014903A/es unknown
- 2021-05-26 DK DK21728553.5T patent/DK4157267T3/da active
- 2021-05-27 TW TW110119170A patent/TW202216149A/zh unknown
-
2024
- 2024-04-15 US US18/635,697 patent/US20240423978A1/en not_active Abandoned
-
2025
- 2025-04-07 US US19/171,900 patent/US20250325543A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023529812A (ja) | 2023-07-12 |
| CA3183434A1 (en) | 2021-12-02 |
| IL298216A (en) | 2023-01-01 |
| AU2021279171A1 (en) | 2023-02-02 |
| EP4157267A1 (en) | 2023-04-05 |
| CN115776889A (zh) | 2023-03-10 |
| DK4157267T3 (da) | 2026-08-03 |
| US20210369709A1 (en) | 2021-12-02 |
| WO2021239786A1 (en) | 2021-12-02 |
| KR20230017830A (ko) | 2023-02-06 |
| US20240423978A1 (en) | 2024-12-26 |
| US20250325543A1 (en) | 2025-10-23 |
| EP4157267B1 (en) | 2026-07-08 |
| CN122376595A (zh) | 2026-07-14 |
| TW202216149A (zh) | 2022-05-01 |
| FI4157267T3 (fi) | 2026-08-12 |
| BR112022023519A2 (pt) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023519A2 (pt) | Tkis de egfr para uso no tratamento de câncer de pulmão de células não pequenas | |
| EA202192552A1 (ru) | Осимертиниб для применения в лечении немелкоклеточного рака легкого | |
| PE20220807A1 (es) | Nuevos inhibidores de egfr | |
| MX2009007987A (es) | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. | |
| Cheng et al. | A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer | |
| GT200600394A (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis. | |
| WO2005017493A3 (en) | Biomarkers in cancer | |
| EA201000093A1 (ru) | Производные пиридазинона | |
| MX382354B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| EA201100966A1 (ru) | Производные пиридазинона | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| UA100540C2 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| MX2013004086A (es) | Metodos para inhibir proliferacion celular en cancers accionados por egfr. | |
| MX2024011959A (es) | Inhibidores de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr) junto con un inhibidor de la akt para el tratamiento del cáncer. | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
| EA201001648A1 (ru) | Производные пиридазинона | |
| MX2020008395A (es) | Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. | |
| ES2723827T3 (es) | Terapia de combinación de fármacos para el tratamiento de tumores sólidos | |
| MX2022008874A (es) | Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer. | |
| EA201101041A1 (ru) | Производные пиридазинона | |
| EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
| CL2024003731A1 (es) | Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer. | |
| BR112018011196A2 (pt) | uso de pirimido-pirimidazinonas para tratar o câncer | |
| MX2010004259A (es) | Tratamientos antitumorales mejorados. |